Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies
View abstract on PubMed
Summary
This summary is machine-generated.Cancer/testis tumour-associated antigens (C/T TAA) are expressed in the testis and various cancers. Their heterogeneous expression suggests C/T TAA are promising targets for multiantigenic cancer vaccines and immunotherapy.
Area Of Science
- Immunology
- Oncology
- Molecular Biology
Background
- Cancer/testis tumour-associated antigens (C/T TAA) were the first human tumour antigens identified at the molecular level.
- Specific genes encoding C/T TAA are expressed in both the testis and diverse tumor types.
- The expression pattern of C/T TAA suggests their potential as targets for active immunotherapy.
Purpose Of The Study
- To review immunohistochemical evidence of C/T TAA expression in human cancers.
- To assess the distribution of C/T TAA within clinical tumor samples.
- To evaluate the potential of C/T TAA as targets for cancer immunotherapy.
Main Methods
- Review of immunohistochemical studies on C/T TAA expression.
- Analysis of serological reagents for C/T TAA characterization and distribution assessment.
- Evaluation of cytotoxic T lymphocyte recognition of C/T TAA.
Main Results
- C/T TAA exhibit heterogeneous expression across various human cancers.
- Serological reagents have aided in understanding C/T TAA biochemistry and distribution.
- Immunohistochemical data confirm the presence of C/T TAA in a wide range of tumors.
Conclusions
- The heterogeneous expression of C/T TAA supports the development of multiantigenic tumor vaccine preparations.
- The broad detection of C/T TAA in diverse cancers warrants further research into effective immunotherapeutic strategies.
- C/T TAA represent promising targets for developing novel cancer immunotherapies.